Agilent Technologies: Ma Activity
Agilent Technologies completed the acquisition of Biocare Medical from Excellere Partners and GHO Capital Partners. Biocare is a global leader in immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions.
Source: GNW — United Kingdom
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in the sector.
Market context: MitchelLake's Talent Market Index sits at 113.8 (Hot), up 13.7 on the prior month; Americas hiring signal is running easing (-3pts).
Agilent Technologies: 2 signals in the last 90 days; 0.2% of MitchelLake's Oceania signal flow; 2 tracked across 22 days.
Also at Agilent Technologies →
More signals across Americas
Ma Activity · Americas
EXL →EXL (NASDAQ: EXLS) agreed to acquire AI model training and evaluation specialist iMerit for up to $310 million ($170M upfront + $140M in earnouts). The deal strengthens EXL's enterprise AI capabilities across model development, reinforcement learning, and foundation model optimization. Expected close Q3 2026.
Ma Activity · Americas
Veolia →Veolia acquired Clean Earth for $3B, expanding its environmental services and waste management portfolio.
Ma Activity · Americas
GMS →GMS acquired the assets of Central Materials, a distributor of stucco, EIFS, stone, masonry, and related cladding products, to expand its South Texas cladding products presence.
Ma Activity · Americas
Wood Mackenzie →Wood Mackenzie acquired LandGate and its 150 million parcel-level land intelligence dataset to strengthen market position in US power, renewables, and data center markets
Ma Activity · Americas
Yum! Brands →Yum! Brands is divesting Pizza Hut through two separate transactions: Pizza Hut outside mainland China to private equity firm LongRange Capital, and Pizza Hut China to Yum China. Total proceeds of $2.3 billion. Strategic focus shift toward KFC and Taco Bell expansion.
Ma Activity · Americas
Eli Lilly and Company →Eli Lilly completed acquisition of clinical-stage Centessa Pharmaceuticals, bringing orexin receptor 2 agonist pipeline for narcolepsy and sleep-wake disorders into Lilly's neuroscience portfolio.
Intelligence powered by Autonodal ↗